ACTRN12617000283370已完成4 期
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in two sites in Yemen.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 110
研究概览
简要总结
A total of 110 patients were recruited, six were lost to follow-up. The remaining 104 cleared parasites by day 3 and achieved adequate clinical and parasitological response on day 28. None of the samples of the study patients carried K13 mutation, marker of artemisinin resistanace.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 60 Weeks（—）
- 性别
- All
入选标准
- •1.age 6 months and above, excluding female minors 12-17 years old and unmarried females aged 18 years and above;
- •2.mono-infection with P. falciparum detected by microscopy;
- •3.parasitaemia of 500-200000 per microL asexual forms;
- •4.presence of axillary temperature greater or equal to 37.5 degrees C or history of fever during the past 24 h;
- •5.ability to swallow oral medication;
- •6.ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7.informed consent from the patient or from a parent or guardian in the case of children aged less than 18 years;
- •8.informed assent from any minor participant aged from 12 to 17 years; and
- •9.consent for pregnancy testing from female of child-bearing potential and from their parent or guardian if under the age of majority years.
排除标准
- •1.presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2.weight under 5 kg;
- •3.mixed or mono-infection with another Plasmodium species detected by microscopy;
- •4.presence of severe malnutrition defined as a child aged 6-60 months who has a mid-upper arm circumference < 115 mm);
- •5.presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •6.regular medication, which may interfere with antimalarial pharmacokinetics;
- •7.history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •8.a positive pregnancy test or breastfeeding; and
- •9.unable to or unwilling to take pregnancy test or to use contraception for married women.
研究者
相似试验
已完成
4 期
Efficacy and safety of artemether- lumefantrine and artesunate - amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mainland TanzaniaInfection - Studies of infection and infectious agentsMalariaACTRN12622001243707ational Institute for Medical Research176
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment ofuncomplicated Plasmodium falciparum malaria in Nangarhar andLaghman, AfghanistaMalariaACTRN12622000873729Ministry of Public Health Afghanistan123
已完成
4 期
Efficacy and safety of Artemether-Lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in different sentinel site in SudaMalariaACTRN12622000930785Ministry of Health212
已完成
4 期
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Al Tor Bin Qais in Hajah, Yemen.Infection - Studies of infection and infectious agentsMalariaACTRN12624000526572The Ministry of Public Health and Population88
尚未招募
不适用
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in AngolaInfection - Studies of infection and infectious agentsMalariaACTRN12615000107527Ministry of Health600